StockNews.com started coverage on shares of Jaguar Health (NASDAQ:JAGX – Free Report) in a research note issued to investors on Saturday. The brokerage issued a sell rating on the biotechnology company’s stock.
Jaguar Health Stock Performance
JAGX opened at $0.09 on Friday. The firm has a 50-day simple moving average of $0.14 and a two-hundred day simple moving average of $0.29. Jaguar Health has a 52 week low of $0.08 and a 52 week high of $4.08. The company has a debt-to-equity ratio of 22.00, a current ratio of 1.77 and a quick ratio of 1.10.
Jaguar Health (NASDAQ:JAGX – Get Free Report) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.38) EPS for the quarter. The company had revenue of $2.81 million for the quarter. Jaguar Health had a negative net margin of 370.40% and a negative return on equity of 1,191.67%. Equities analysts predict that Jaguar Health will post -5.83 EPS for the current year.
Institutional Trading of Jaguar Health
About Jaguar Health
Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
- Five stocks we like better than Jaguar Health
- Canada Bond Market Holiday: How to Invest and Trade
- 3 attractive stocks that insiders are buying
- There Are Different Types of Stock To Invest In
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to Invest in Grocery Stores
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.